• Hikma announces regulatory submissions for its epinephrine nasal spray in the US, UK, Europe, and Canada

  According to Hikma Pharmaceuticals, regulators in the US, Europe, and the UK have accepted submissions for the company’s epinephrine nasal spray for the treatment of anaphylaxis, and the company has also filed a submission in… [Read more . . .]

• Ethris gets €30 million financing through the European Investment Bank and the EC’s Health Emergency Preparedness and Response Authority for development of inhaled and nasal mRNA vaccines

  Inhaled mRNA developer Ethris has signed an agreement with the European Investment Bank (EIB), and the European Commission’s Health Emergency Preparedness and Response Authority (DG HERA) for a €30 million financing to support clinical development… [Read more . . .]

• Pulmovant says Phase 2 PHocus trial of its mosliciguat DPI met its primary endpoint, Phase 3 PHrontier trial has been initiated

  Pulmovant has announced that the Phase 2 PHocus clinical trial of its inhaled dry powder mosliciguat in patients with pulmonary hypertension due to interstitial lung disease (PH-ILD) met its primary endpoint, demonstrating a significant reduction in… [Read more . . .]

• Glenmark launches Ryaltris olopatadine / mometasone nasal spray in Brazil

  Glenmark Pharmaceuticals has announced that Ryaltris olopatadine / mometasone nasal spray was approved by ANVISA earlier this year for the treatment of allergic rhinitis in patients aged 12 and over and that the company has… [Read more . . .]

• Proveris Scientific names Daniel Tereau as President and CEO

  OINDP instrument and testing specialist Proveris Scientific, which was acquired by Investindustrial earlier this year, has announced that experienced life sciences executive Daniel Tereau is the company’s new President and Chief Executive Officer 2026. Tereau was most… [Read more . . .]

• Leyden Labs reveals that it has acquired RIGImmune and announces results from a Phase 1 trial of RIG-101 intranasal antiviral

• MannKind and Rose Pharma partner on development of ROSE-010 Technosphere GLP-1 DPI for weight loss

• AirNexis announces results from Haisco’s Phase 2b trial of AN01 PDE3/4 inhibitor DPI in patients with COPD

• Rezubio initiates Phase 1 trial of RZ-520 inhaled therapy in development for the treatment of respiratory diseases

• FDA grants Fast Track designation to Liquidia’s Yutrepia treprostinil DPI for the treatment of Raynaud’s phenomenon in systemic sclerosis

More news . . .